John L. Fahey, M.D.

A Short Biography:

The research activities focus on understanding the immune system disorders of disease and the effects of immune-based therapies. Cytokine dysregulation in HIV infection with deficiencies of IL-2, excessive interferon-gamma, altered regulatory cytokines and monocyte/macrophage activation are significant aspects of HIV-induced pathology. Investigations of immune based therapies of aging and stress are performed. The major concern is on the changes in immune functions, activation and lymphocyte subset redistribution and the neuroendocrine factors that contribute to these changes.

Work Titles
UCLA Director, CIRID: Center for International Research in Disease Professor, Microbiology, Immunology & Molecular Genetics Member, Basic/Translational Research, Jonsson Comprehensive Cancer Center
Education:
Degrees:
M.D., Harvard Medical School
M.S., Wayne State Medical School

Contact Information:

Email Address:

jlfahey@mednet.ucla.edu


Fax Number:

310-206-1318

Work Phone Number:

310-825-6568

Work Address:

17-328A CHS
Mail Code 736422
Los Angeles, CA 90095


Detailed Biography:

John L. Fahey is an immunologist, clinical researcher and educator who joined the UCLA School of Medicine faculty in 1971 as professor and chair (1971-1981) of the Department of Microbiology and Immunology and a joint appointment in the Department of Medicine. He was a major participant (with 4 other faculty) in the three original UCLA grant applications to the National Cancer Institute, NIH for Planning, for Comprehensive designation and for Construction (1/2 of Factor Building) of the Comprehensive Cancer Center at UCLA (1971-1981). He was Principal Investigator (with 10 associated faculty) for the Center for Interdisciplinary Research in Immunology and Disease, CIRID at UCLA, (1978-1998). John Fahey was PI on NIH Program Project grant on Immune Functions and Cancer (1972-1982). Also he originated two NIH Training Grants at UCLA: Clinical and Fundamental Immunology NIAID and Tumor Immunology NCI (1975). They have continued for more than 30 years under new leadership. Dr. Fahey was founding President of the Clinical Immunology Society (1986) and head of Clinical Immunology Section of the International Union of Immunological Societies (1992-1998). He was a designated Advisor for Immunology to the World Health Organization (1964-1994). He served on NIH Study Sections (1970-1976) and was Member, Council of the NIAID (1979-1985). He was a Member, US-Japan Cooperative Program on AIDS (1991-1995), Consultant to WHO and Faculty for WHO Centers for Immunology Research and Education in Eastern Europe, Africa and Southeast Asia (1964-1974). He has mentored more than 70 US and International postdoctoral scientists with MD or PhD qualifications for careers in biomedical research. In the past decade, he has concentrated on UCLA programs with India and has helped more than a dozen UCLA faculty to conduct educational and research programs in India or guide Indian scientists who are training at UCLA. Professional Activities – Research Selected from over 400 Publications 1. Human Blood Coagulation System: After Factor 5 was discovered Fahey JL, Ware AG and Seegers WH. Stability of prothrombin and Ac-globulin in stored human plasma as influenced by conditions of storage. Am J Physiol. 1948; 154:122-133. 2. Wegener’s Granulomatosis Fahey JL, Leonard E, Churg J and Godman G. Wegener’s granulomatosis. Am J Med. 1954; 17:168-179. 3. Ammonia toxicity with amino acid infusions Fahey JL. Toxicity and blood ammonia rise resulting from intravenous amino acid administration in man: The protective effect of L-arginine. J Clin Invest. 1957; 36:1647-1655. 4. Introduction of Plamsapheresis therapy for Hyperviscosity Syndrome Schwab PJ and Fahey JL. Treatment of Waldenstrom’s macroglobulinemia by plasmapheresis. N Engl J Med. 1960; 263:574-579 Fahey JL, Barth WF and Solomon A. Serum hyperviscosity syndrome. JAMA. 1965 May 10; 192:464-467. 5. Human Immunoglobulin System a. Discovery of IgD Rowe DS and Fahey JL. A new class of human immunoglobulins: II. Normal serum IgD. J Exp Med. 1965; 121:185-199. Rogentine GN, Jr, Rowe DS, Bradley J, Waldmann TA and Fahey JL. Metabolism of human immunoglobulin D (IgD). J Clin Invest. 1966; 45:1467-1478. b. Identification of IgG subclasses Terry WL and Fahey JL. Subclasses of human gamma2-globulins: (IgG) based on differences in the heavy polypeptide chains. Science. 1964; 146:400-402. Fahey JL, Franklin EC, Kunkel HG, Osserman EF and Terry WD. Notation for human immunoglobulin subclasses. J Immunol. 1967 Aug; 99(2):465. c. Relation of structure to function Fahey JL and Robinson AG. Factors controlling serum gamma-globulin concentration. J Exp Med. 1963; 118:845-868. Sell S and Fahey JL. Gamma globulin metabolism in germ-free mice. J Immunol. 1964; 93:81-87. Barth WF and Fahey JL. Heterologous and homologous skin sensitizing activity of mouse 7S1 and 7S2-globulins. Nature. 1965; 206:730-731. d. Production and Metabolism Fahey JL, Finegold I, Rabson AS and Manaker RA. Immunoglobulin synthesis in vitro by established human cell lines. Science. 1966 May 27; 152(726):1259-1261. Buell DN and Fahey JL. Limited periods of gene expression in immunoglobulin-synthesizing cells. Science. 1969 Jun; 164(887):1524-1525. e. Quantitative Methods: Plasma Ig Levels in Disease Fahey JL and Lawrence ME. Quantitative determination of 6.6S gamma-globulins, beta2A-globulins and gamma1-macroglobulins in human serum. J Immunol. 1963; 91:597-603. McKelvey EM and Fahey JL. Immunoglobulin changes in disease: Quantitation of heavy polypeptide chain classes, IgG, IgA and IgM, and light polypeptide chain types IgK (Type I) and IgL (Type II). J Clin Invest. 1965; 44:1778-1787. f. Genetic Studies Fahey JL and Lawler SD. Gm factors in normal gamma globulin fractions, myeloma proteins and macroglobulins. J Natl Cancer Inst. 1961; 27:973. Terry WD, Fahey JL and Steinberg AG. Em and Inv factors in subclasses of human IgG. J Exp Med. 1965; 122:1087-1102. 6. Murine Immunoglobulin System a. Identification of major Ig Classes and Subclasses Fahey JL, Wunderlich J and Mishell R. The immunoglobulins of mice: I. Four major classes of immunoglobulins: 7S gamma2, 7S gamma1, gamma1A (beta 2A) and 18Sgamma 1M-globulins. J Exp Med. 1964; 120:223-242. Fahey JL, Wunderlich J and Mishell R. The immunoglobulins of mice: II. Two subclasses of mouse 7S gamma2-globulins: gamma2A and gamma2B-globulins. J Exp Med. 1964; 120:243-251. Barth WF, McLaughlin CL and Fahey JL. The immunoglobulins of mice. VI. Response to immunization. J Immunol. 1965; 95:781-790. b. Regulation of IgG plasma levels Fahey JL and Robinson AG. Factors controlling serum gamma-globulin concentration. J Exp Med. 1963; 118:845-868. Sell S and Fahey JL. Gamma globulin metabolism in germ-free mice. J Immunol. 1964; 93:81-87. Fahey JL and Barth WF. The immunoglobulins of mice. IV. Serum immunoglobulin changes following birth. Proc Soc Exp Biol. and Med. 1965; 118:596-600. c. Murine Myeloma and Bence Jones protein Fahey JL. Immunological studies of twenty mouse myeloma proteins: Evidence for two groups of proteins similar to gamma and beta-2A globulins in man. J Exp Med. 1961; 144:385-398. Fahey JL and Sell S. The immunoglobulins of mice. V. The metabolic (catabolic) properties of five immunoglobulin classes. J Exp Med. 1965; 122:41-58. d. Studies of murine plasmacytomes (multiple myeloma) Potter M and Fahey JL. Studies on eight transplantable plasma-cell neoplasms of mice. J Natl Cancer Inst. 1960; 24:1153-1165. Fahey JL and Humphrey JH. Effect of transplatable plasma cell tumors on antibody response in mice. Immunology. 1962; 5:110-115. 7. AIDS a. Initial Discovery – Identified characteristic T cell changes Gottlieb, M.S., Weisman, J.D., Fan, P.T. et al. Pneumocystis carinii pneumonia and mucosal candidiasis in previously healthy homosexual men: Evidence for a new severe acquired cellular Immunodeficiency. N. Engl. J. Med. 305:1425-1431, 1981. b. Immunopathogenesis including immune activation Fahey JL, Prince H, Weaver MM, Groopman J, Visscher B, Schwartz K and Detels R. Quantitative changes in Th or Ts lymphocyte subsets that distinguish AIDS syndrome from other immune subset disorders. Am J Med. 1984; 76:95-100. Fahey JL, Taylor JMG, Detels R, Hofmann B, Melmed RN, Nishanian P and Giorgi JV. The prognostic value of cellular and serologic markers in infection with human immunodeficiency virus type 1. N Eng J Med. 1990; 322:166-172. Popow J, McGraw T, Hofmann B, Vowels B, Shum A, Nishanian P and Fahey JL. Acute lymphoid changes and ongoing immune activation in SIV infection. J Acquir Immun Defic Syndr. 1992; 5:391-399. c. Epidemiology with MultiCenter AIDS Cohort Study (MACS) Detels R, Visscher BR, Fahey JL, Sever JL Gravell M, Madden DL, Schwartz K, Dudley J, English PA, Powers H, Clark VA and Gottlieb MS. Predictors of clinical AIDS in young homosexual men in a high-risk area. Intl J Epi. 1987; 16(2):271-276. Detels R, English PA, Giorgi JV, Visscher BR, Fahey JL, Taylor JMG, Dudley JP, Nishanian P, Munoz A, Phair JP, Polk BF and Rinaldo CR. Patterns of CD4+ cell changes after HIV-1 infection indicate the existence of a codeterminant of AIDS. J Acquir Immun Defic Syndr. 1988; 1(4):390-395. Fahey JL. Cytokines, plasma immune activation markers and clinically relevant surrogate markers in Human Immunodeficiency Virus infection. Clin Diagn Lab Immunol. 1998; 5: 597-603. d. Therapy with AIDS Clinical Trial Group (ACTG) Bass HZ, Hardy WD, Mitsuyasu RT, Taylor JMG, Wang YX, Fischl M, Spector SA, Richman DD and Fahey JL. The effect of zidovudine treatment on serum neopterin and beta-2 microglobulin levels in mildly symptomatic, HIV type 1 seropositive individuals. J Acquir Immun Defic Syndr. 1992; 5:215-221. Jacobson JM, Greenspan JS, Spritzler J, Ketter N, Fahey JL, Jackson JB, Fox L, Chernoff M, Wu AW, MacPhail LA, Vasquez GJ, and Wohl DA. Thalidomide for the treatment of oral aphthous ulcers in patients with Human Immunodeficiency Virus infection. N Engl J Med. 1997 May 22; 336(21):1487-1493. Mitsuyasu R, Gelman R, Cherng DW, Landay A, Fahey JL, Reichman R, Erice A, Bucy P, Kilby, JM, Lederman MM, Dukes-Hamilton C, Lertora J, van der Horst C, Tebas P, Duliege A-M, Pollard RB and the ACTG 328 Study Team. The Virologic, Immunologic and Clinical Effects of Interleukin-2 with Potent Antiretroviral Therapy in Patients with Moderately Advanced HIV Infection: A Randomized Controlled Clinical Trial-ACTG 328. Arch Int Med, March 26, 2007, 167:597-605. 8. Nervous-Immune System Interactions including Psychoneuroimmunology Kemeny M, Weiner H, Taylor SE, Schneider S, Visscher B and Fahey JL. Repeated bereavement, depressed mood and immune parameters in HIV seropositive and seronegative homosexual men. Health Psychol. 1994; 13(1):14-24. Futterman AD, Kemeny ME, Shapiro D and Fahey JL. Immunological and physiological changes associated with induced positive and negative mood. Psychosomatic Medicine. 1994; 56:499-511. Cole S, Kemeny ME, Fahey JL, Zack JA and Naliboff BD. Psychological Risk Factors for HIV Pathogenesis: Mediation by the Autonomic Nervous System. Biol Psychiatry. 2003 Dec 15; 54(12):1444-56. 9. Clinical Laboratory Immunology Fahey JL, Aziz N, Spritzler J, Plaeger S, Nishanian P, Lathey JL, Landay AL, Schmitz JL, Wara DW, McElrath J, Douglas SD, Reuben J, Shearer WT, Nokta M, Polland R, Schooley R, Asthana D, Mizrachi Y, and Waxdal M. Need for an External Proficiency Testing Program for Cytokines, Chemokines and Plasma Markers of Immune Activation. Clin Diag Lab Immunol. 2000; 7(4):540-548. Mandy F, Bergeron M, Houle G, Bradley J, and Fahey JL. The Impact of the International Program for Quality Assessment and Standardization for Immunological Measures Relevant to HIV/AIDS: QASI. Clinical Cytometry. 2002 April 15; 50(2):111-116.

Does this profile need updating? Contact Us